Literature DB >> 21420818

HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients.

M N Vogel1, M Vatlach, P Weissgerber, B Goeppert, C D Claussen, J Hetzel, M Horger.   

Abstract

OBJECTIVE: This study retrospectively analyzes the characteristics and kinetics of pulmonary changes in Pneumocystis jiroveci pneumonia (PJP) before and after treatment as depicted by thin-section-CT in HIV-negative patients.
MATERIALS AND METHODS: Serial CT scans of 84 consecutive HIV-negative PJP patients were reviewed retrospectively encompassing a median follow-up of 76 (range, 37-506) days. Along with underlying disease and time span between the onset of symptoms and specific antimicrobial therapy, early and late pulmonary CT-findings were evaluated.
RESULTS: Imaging findings at initial diagnosis differed from those in the posttherapeutic setting. In the acute (initial) PJP-phase, most frequent finding was symmetric, apically distributed ground glass opacities (GGO) with peripheral sparing 43% (n = 36). These initial changes resolved up to 1st follow-up-examination in 57% (n = 48), and finally in all except for two patients after a median period of 13 (mean 26, range 1-58) days following application of specific therapy. In 42% (n = 35) architectural distortions occurred, but they resolved after a median period of 27 (mean 60, range 11-302) days. Only in 9 patients, complete resolution could not be documented. Significant correlations of the underlying disease or the time span between the onset of symptoms and specific antibiotic therapy and morphologic kinetic could not be found.
CONCLUSION: Thin-section CT-findings of PJP usually resolve soon after onset of specific therapy. Postinfectious fibrosis rarely occurs following PJP in HIV-negative patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21420818     DOI: 10.1016/j.ejrad.2011.02.052

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  25 in total

1.  Pneumocystis jirovecii pneumonia presenting as a solitary pulmonary granuloma due to unclean continuous positive airway pressure equipment: a case report.

Authors:  Lun-Yu Jao; Wen-Lin Su; Hsu-Chao Chang; Chou-Chin Lan; Yao-Kuang Wu; Mei-Chen Yang
Journal:  J Clin Sleep Med       Date:  2022-06-01       Impact factor: 4.324

2.  Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus.

Authors:  Katrien Lagrou; Sharon Chen; Henry Masur; Claudio Viscoli; Catherine F Decker; Livio Pagano; Andreas H Groll
Journal:  Clin Infect Dis       Date:  2021-03-12       Impact factor: 9.079

3.  Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death.

Authors:  Minjiang Chen; Xinlun Tian; Fang Qin; Jiong Zhou; Jinjing Liu; Mengzhao Wang; Kai-Feng Xu
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

Review 4.  Glucocorticosteroid in treatment of severe pneumonia.

Authors:  Felinda Ariani; Kaixiong Liu; Zhang Jing; Jieming Qu
Journal:  Mediators Inflamm       Date:  2013-12-02       Impact factor: 4.711

5.  Clinical Usefulness of HRCT in Assessing the Severity of Pneumocystis jirovecii Pneumonia: A Cross-sectional Study.

Authors:  Chung-Wei Chou; Heng-Sheng Chao; Fang-Chi Lin; Han-Chen Tsai; Wei-Hsin Yuan; Shi-Chuan Chang
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

6.  Mimics in chest disease: interstitial opacities.

Authors:  Anastasia Oikonomou; Panos Prassopoulos
Journal:  Insights Imaging       Date:  2012-12-18

Review 7.  Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review.

Authors:  Magdalena Sokulska; Marta Kicia; Maria Wesołowska; Andrzej B Hendrich
Journal:  Parasitol Res       Date:  2015-08-19       Impact factor: 2.289

8.  Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  G Maschmeyer; J Carratalà; D Buchheidt; A Hamprecht; C P Heussel; C Kahl; J Lorenz; S Neumann; C Rieger; M Ruhnke; H Salwender; M Schmidt-Hieber; E Azoulay
Journal:  Ann Oncol       Date:  2014-05-15       Impact factor: 32.976

9.  Relationship between Radiological Stages and Prognoses of Pneumocystis Pneumonia in Non-AIDS Immunocompromised Patients.

Authors:  Xiang-Dong Mu; Peng Jia; Li Gao; Li Su; Cheng Zhang; Ren-Gui Wang; Guang-Fa Wang
Journal:  Chin Med J (Engl)       Date:  2016-09-05       Impact factor: 2.628

10.  Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study.

Authors:  Li Weng; Xu Huang; Lie Chen; Li-Qin Feng; Wei Jiang; Xiao-Yun Hu; Jin-Min Peng; Chun-Yao Wang; Qing-Yuan Zhan; Bin Du
Journal:  BMC Infect Dis       Date:  2016-09-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.